ArticleFrontiers in immunology2025
The role of eosinophils and their activation state in hypereosinophilia-associated heart disease.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Background: Cardiac complications in patients with hypereosinophilia cause significant morbidity and mortality. However, mechanisms of how eosinophilic inflammation causes heart damage are poorly understood. Methods: We developed a model of hypereosinophilia-associated heart disease by challenging hypereosinophilic mice with a peptide from the cardiac myosin heavy chain. Disease outcomes were measured by histology, immunohistochemistry, flow cytometry, and measurement of cells and biomarkers in peripheral blood. Eosinophil dependence was determined by using eosinophil-deficient mice (ΔdblGATA). Single cells from the heart were subjected to single-cell RNA sequencing to assess cell composition, activation states, and expression profiles. Results: Mice challenged with the myocarditic and control peptide had peripheral blood leukocytosis, but only those challenged with the myocarditic peptide had heart inflammation. Heart tissue was infiltrated by eosinophil-rich inflammatory infiltrates associated with cardiomyocyte damage. Disease penetrance and severity were decreased in eosinophil-deficient mice. Single-cell RNA sequencing showed the enrichment of myeloid cells, T cells, and granulocytes (neutrophils and eosinophils) in myocarditic mice. Focusing on eosinophils, there was increased expression of genes associated with type 1 cell activation (such as CD274/PDL1), complement activation, and pathogen-associated molecular pattern recognition. To verify findings generated by single-cell RNA sequencing on a protein level, we performed flow cytometry analysis and assessed the level of type 1 and type 2 biomarkers CD274 and CD101, respectively. The proportion of cells expressing surface CD274 increased on both neutrophils and eosinophils, particularly in mice that showed inflammation by histology. There was no significant increase in expression of CD101. Finally, we assessed whether activation markers can be induced on eosinophils Conclusion: Eosinophils are required for heart damage in hypereosinophilia-associated heart disease. Heart-infiltrating eosinophils in an inflammatory condition show type 1 activation, which can be recapitulated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.